Combining circulating tumor cells and tumor-derived extracellular vesicles for prognosis stratification in patients with metastatic breast cancer.
Measuring two types of cancer markers in blood together better predicts survival in advanced breast cancer, enabling sharper risk stratification.
Reanalysis of CellSearch images from 355 MBC patients established a tdEV cut-off of >20/7.5ml independently predicting nearly doubled mortality risk, with CTChigh/tdEVhigh combination identifying the worst prognostic subgroup. Validation in a STIC CTC Phase III trial subcohort (n=385) confirmed complementary prognostic value of tdEVs among CTClow patients, supporting combined CTC+tdEV profiling for MBC clinical trial stratification.
What the study was
- Study design
- cohort_study
- Population
- Metastatic breast cancer patients: NU16B06 training cohort (n=355) and STIC CTC Phase III validation cohort (n=385)
- Sample size
- 740
- Category
- Liquid Biopsy / Prognosis
- Maturity
- Validated
- Journal
- ESMO Open
Why it surfaced
Two-cohort validation (training n=355 + Phase III validation n=385) of tdEV as CTC complement in MBC; CellSearch-compatible ACCEPT software; independent prognosis in CTClow subgroup; ESMO Open; Institut Curie and Weill Cornell collaboration.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.